



## NEWS RELEASE

### DR. JACK GAULDIE AND MR. JOHN HYSHKA JOIN DEFYRUS BOARD OF DIRECTORS

For Immediate Release

August 20<sup>th</sup>, 2009

---

**Toronto** - Defyrus Inc. today announced that Dr. Jack Gauldie and John Hyshka have joined the Board of Directors of Defyrus.

An expert in cytokine biology, inflammation and immunology, Dr. Gauldie is Director of McMaster University's Centre for Gene Therapeutics which implements state-of-the-art gene transfer therapies for cancer and inflammatory and infectious diseases. Dr. Gauldie has been the Professor and Chair of the Department of Pathology and Molecular Medicine at McMaster for the past 15 years and is a Fellow of the Royal Society of Canada. He is currently the Director of McMaster's new Institute for Molecular Medicine and Health.

John Hyshka is the Chief Operating Officer and Chief Financial Officer for Phenomenome Discoveries Inc, a human health research company that uses its patented metabolomic biomarker discovery platform and informatic research tools to discover novel metabolite biomarkers. Mr. Hyshka is also a Director of Economic Development for the Saskatoon Regional Economic Development Authority and a former Director of the Business Development Bank of Canada.

David F. Masotti, Chairman of Defyrus said: "We are delighted to have Dr. Gauldie and Mr. Hyshka join our Board. Professor Gauldie is a world expert in the use of gene therapy for the creation and delivery of Adenoviral-based drugs and vaccines. Mr. Hyshka brings considerable strategic, operational and product development experience to the Board. Their combined scientific, clinical and business experience is valuable to Defyrus as we complete the development of our medical countermeasures.

"The Defyrus team led by Dr. Jeffrey Turner, has an outstanding track record in the development and commercialization of medical countermeasures", commented Dr. Gauldie. "I look forward to working with the company during this period of exciting growth".

Mr. Hyshka added that "the Company's licensed technology of 27 issued and pending international patents is impressive and provides the necessary Adenoviral-based platform for the production of broad spectrum anti-viral drugs and multi-valent vaccines for the treatment of infections resulting from bioterrorism or endemic disease. I am delighted to be joining the Board at this time."



**About Defyrus**

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and vaccines as medical countermeasures to bioterrorist threats and emerging infectious diseases. [www.defyrus.com](http://www.defyrus.com)

###

**For further information:**

Dr. Jeffrey D. Turner  
President & CEO  
Tel: (613) 674-1138  
info@defyrus.com

Mr. Dana Rath  
Chief Financial Officer  
Tel: (514) 231-3554  
info@defyrus.com